We are live on ! Find out more
APYX icon

Apyx Medical

56 hedge funds and large institutions have $93.1M invested in Apyx Medical in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

138% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 8

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

90% more capital invested

Capital invested by funds: $49M → $93.1M (+$44.1M)

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

19% more funds holding

Funds holding: 4756 (+9)

Holders
56
Holders Change
+9
Holders Change %
+19.15%
% of All Funds
1.28%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
17
Increased
19
Reduced
8
Closed
8
Calls
$45K
Puts
Net Calls
+$45K
Net Calls Change
+$45K

APYX Hedge Fund Activity: Q3 2018 in Review

56 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Apyx Medical (APYX) for Q3 2018, worth a combined $93.1M — up 90% from $49M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new APYX positions and 8 closed out — a net gain of 9 holders — while 19 added to existing stakes and 8 trimmed.

The largest buyer was EAM Investors, opening a new position worth an estimated $1.66M. The largest seller was Archon Capital Management, cutting an estimated $1.35M.

  • 56 institutional investors held Apyx Medical (APYX) as of Q3 2018, up from 47 in Q2 2018.
  • Funds reported $93.1M of Apyx Medical stock for Q3 2018, up 90% quarter-over-quarter.
  • 17 funds opened new Apyx Medical positions in Q3 2018 and 8 closed out, a net change of +9 holders.
  • The largest Apyx Medical buyer in Q3 2018 was EAM Investors, an estimated $1.66M added.
  • The largest Apyx Medical seller in Q3 2018 was Archon Capital Management, an estimated $1.35M sold.

Based on aggregated 13F filings for Q3 2018.